Skip to Content
MilliporeSigma
All Photos(1)

Documents

07741

Supelco

Everolimus

analytical standard

Synonym(s):

CERTICAN®, 42-O-(2-Hydroxyethyl)rapamycin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C53H83NO14
CAS Number:
159351-69-6
Molecular Weight:
958.22
MDL number:
MFCD00929329
UNSPSC Code:
41116107
PubChem Substance ID:
329748511

grade

analytical standard

assay

≥95% (HPLC)

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

storage temp.

−20°C

SMILES string

O=C(C([C@@]1(O)[C@H](C)CC[C@](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)([H])O1)=O)N3[C@H](C(O[C@@]([C@@H](C[C@@]4([H])C[C@@H](OC)[C@H](OCCO)CC4)C)([H])CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)=O)CCCC3

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChI key

HKVAMNSJSFKALM-GKUWKFKPSA-N

Gene Information

human ... FKBP1A(2280)

Looking for similar products? Visit Product Comparison Guide

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Analysis Note

Exact concentration and expiry date can be found on the certificate, included in each package.

Legal Information

CERTICAN is a registered trademark of Novartis AG

related product

Product No.
Description
Pricing

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Warning

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Repr. 2 - STOT RE 2

target_organs

Kidney,Testes

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCBS2040V
BCBR8517V
BCBP8733V
BCBP1603V
BCBM2224V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Palbociclib ≥98% (HPLC)

Sigma-Aldrich

PZ0383

Palbociclib

Inge Verbrugge et al.
Radiation research, 182(2), 219-229 (2014-06-25)
Radiotherapy is a successful treatment modality for localized cancer. Our group has been exploring radiotherapy in combination with immunotherapy (radioimmunotherapy) to enhance systemic antitumor responses. Previously, we have shown that when local radiotherapy was combined with monoclonal antibodies (mAbs) (that
Atsushi Ohtsu et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(31), 3935-3943 (2013-09-18)
The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, double-blind, phase III study compared everolimus efficacy and safety with that of best supportive care (BSC) in
Alfonso Ielasi et al.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 89(7), 1129-1138 (2016-10-25)
To assess the feasibility and the clinical results following a prespecified bioresorbable vascular scaffold (Absorb BVS) implantation strategy in ST-elevation myocardial infarction (STEMI) patients. Concerns raised about the BVS safety in STEMI setting because a not negligible thrombosis rate was
Joëlle Elias et al.
Heart (British Cardiac Society), 104(17), 1432-1438 (2018-02-22)
During primary percutaneous coronary intervention (PCI), a concurrent chronic total occlusion (CTO) is found in 10% of patients with ST-elevation myocardial infarction (STEMI). Long-term benefits of CTO-PCI have been suggested; however, randomised data are lacking. Our aim was to determine
Simron Singh et al.
Neuroendocrinology, 106(3), 211-220 (2017-05-30)
The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service